flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, will be hosting its second R&D Day today, Wednesday, May 22, 2019, in New York starting at 8:30am ET. During the event, argenx will present data on two new pipeline candidates that emerged from its Innovative Access Program (IAP) and will provide updates on the development plan of cusatuzumab (ARGX-110) in collaboration with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. Today, argenx will also bring forward its “argenx 2021” vision, providing clarity on its strategy to become a fully integrated immunology company.
OCTIMET Oncology announces the appointment of Shelley Margetson as CEO
OCTIMET Oncology, a clinical-stage biotech company with a focus on the development of highly specific and differentiated oral kinase inhibitors, announces the appointment of Shelley Margetson as CEO. Timothy Perera PhD, founder of the company, will continue as CSO.
Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that a multi-centered study on the performance of the Idylla(TM) MSI Test (CE IVD) in comparison with the Promega MSI test ('Promega MSI Test') has been selected for publication at the renowned ASCO (American Society of Clinical Oncology) Annual Meeting. The study showed high performance and a low invalid rate of the Idylla(TM) MSI Test, as such demonstrating the possibility of rapid, fully automated MSI testing with Idylla(TM). The ASCO conference takes place between 30 May and 4 June 2019 in Chicago (IL), US.
Brain imaging AI leader icometrix raises $18 million in new funding
Leuven/Geneva/Boston icometrix, the global expert in brain imaging Artificial Intelligence solutions, has raised $18 million through a partnership led by Forestay Capital alongside Optum Ventures and existing investor Capricorn Venture Partners.